- Q1 2024 Humacyte Inc Earnings Call TranscriptMay 10, 2024$4.7 (+3.98%)Earnings
- Q4 2023 Humacyte Inc Earnings Call TranscriptMar 22, 2024$3.31 (-8.06%)Earnings
- Q3 2023 Humacyte Inc Earnings Call TranscriptNov 09, 2023$2.21 (+0.91%)Earnings
- Humacyte Inc To Host KOL And Patient Perspectives Event TranscriptSep 20, 2023
- Humacyte Inc Top Line Data Announcement TranscriptSep 12, 2023
- Q2 2023 Humacyte Inc Earnings Call TranscriptAug 14, 2023$4.04 (+23.55%)Earnings
- Q1 2023 Humacyte Inc Earnings Call TranscriptMay 12, 2023$3.97 (-6.48%)Earnings
- Humacyte Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Q4 2022 Humacyte Inc Earnings Call TranscriptMar 24, 2023$2.91 (-5.83%)Earnings
- Humacyte Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Humacyte Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Humacyte Inc At Emerging Growth Conference (Virtual) TranscriptFeb 08, 2023
- Humacyte Inc KOL Webinar: Ukrainian Surgeons Discuss Use of HAV in Wartime TranscriptDec 15, 2022
- Q3 2022 Humacyte Inc Earnings Call TranscriptNov 10, 2022$3.26 (+3.82%)Earnings
- Q4 2021 Humacyte Inc Earnings Call TranscriptMar 29, 2022$6.73 (+5.65%)Earnings
Humacyte Inc at Cowen Health Care Conference Transcript
(audio in progress)
-- doing and what it's going to do in the future. And certainly, if I should gloss over anything too quickly, then we'd be happy to talk with any of the audience participants after the talk.
So this is just our standard disclaimer. So Humacyte is really a first-in-class regenerative medicine technology company. We are the only company in the world that engineers replacement human tissues, basically spare parts for people, in a way that is at commercial scale and in a way that the tissues themselves are universally implantable. They can go into any human recipient without rejection. And that makes us unique in the field of regenerative medicine.
We have received FDA designation of Regenerative Medicine Advanced Therapy, or RMAT designation, as well as a Defense Department priority designation in the last several years. The total markets that Humacyte estimates it can address, the total addressable markets worldwide, are about $150 billion. The reason our total addressable markets are so large is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)